Report Overview

The Bone diseases Drug market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The most common disease affecting bones is Osteoporosis. It is a Bone-Mineral Density (BMD) disease in which the bones become weak and brittle due to loss of bone density which increases the risk of fractures. The World Health Organization (WHO) operationally defines osteoporosis as a Bone Mineral Density (BMD) that falls 2.5 Standard Deviations (SD) below the mean for young healthy adults. Osteoporosis is common among females above age 50 due to menopause. A positive association between osteoporosis and advancing age, poverty, illiteracy, and being underweight was found. In Kenya, the prevalence of osteoporosis stands at 24.3%. It is often overlooked and undertreated because it is clinically silent unless it presents with a fracture. Osteoporosis is not regarded as a health priority in Kenya. Despite ample sunshine, Africa registers the highest rates of rickets worldwide. Low levels of vitamin D cause Osteomalacia in adults and Rickets in children.

Market Drivers

The market is majorly driven due to the rising prevalence of bone diseases in urban population caused due to adoption of modern lifestyles, physical inactivity, dietary changes, and hormonal changes due to ageing. A Kenyan study, in a hospital-based setting reported rates of osteopenia in pre- and post-menopausal women to be 20.5% and 32% respectively.

The increase in the prevalence of bone diseases is also attributed to increased alcohol consumption and smoking, low levels of Vitamin D and underlying medical conditions like chronic kidney disease (CKD). Osteoporosis is males is attributed to decline in the testosterone levels with ageing.

Over the past few decades, there has been increase in focus towards female health in the country that has led to increase in the awareness levels among women.

However, the side effects caused by the drugs is one of the restraining factors. Some of the drugs have been found to have carcinogenic effect.

Diagnosis is a challenge due to low index of suspicion and due to the limited number of DEXA machines in the country and Africa as a whole. Kenya has 2 DEXA machines that serve a population of 40 million and the greater East Africa region. This limits the growth of bone diseases Drug market.